Syngene International Limited — Important, 21-02-2025: Updates

The USFDA recently conducted a pre-approval and cGMP inspection at Syngene International's Bengaluru facilities, assessing their commercial manufacturing activities for the US market. The inspection, which took place from February 10 to February 20, resulted in the issuance of Form 483, which included five observations. Syngene is committed to addressing these observations in a timely manner, collaborating closely with the USFDA. This development is crucial for the company’s ability to continue supporting its operations in the US market and could have implications for future business growth and regulatory compliance. Investors should monitor this situation for any updates regarding the resolution of the observations and its potential impact on operations.